Immunotherapy plus chemo shows promise for rare sinus cancer

NCT ID NCT05925491

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy before surgery can shrink advanced sinonasal undifferentiated carcinoma (SNUC), a rare and aggressive sinus cancer. About 28 adults with newly diagnosed, locally advanced SNUC will receive the combination, then surgery, followed by more pembrolizumab. The goal is to improve tumor response and reduce side effects compared to chemotherapy alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SINONASAL UNDIFFERENTIATED CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sinonasal undifferentiated carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Istituti Clinici Scientifici Maugeri

    RECRUITING

    Pavia, Lombardy, 27100, Italy

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••